Three months before a young boy died in Huidagene’s gene editing trial last year, the company’s former CEO Alvin Luk presented its early data at the American Society for Gene and Cell Therapy’s Presidential Symposium, one of the field’s biggest stages.
STAT asked several experts in gene editing and muscle disorders to review video of the presentation. They came away divided — often starkly — on the quality of the company’s science and the wisdom of the approach.
“I’m not impressed,” said Dongsheng Duan, who has spent a decade studying gene editing for Duchenne at the University of Missouri, in an email.